Benitec Biopharma (BNTC) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

BNTC Stock Forecast

Benitec Biopharma stock forecast is as follows: an average price target of $20.33 (represents a 78.18% upside from BNTC’s last price of $11.41) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

BNTC Price Target

The average price target for Benitec Biopharma (BNTC) is $20.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $13.00. This represents a potential 78.18% upside from BNTC's last price of $11.41.

BNTC Analyst Ratings

Buy

According to 5 Wall Street analysts, Benitec Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for BNTC stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Benitec Biopharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 14, 2024	Silvan Tuerkcan	JMP Securities	$18.00	$10.86	65.75%	57.76%
Oct 14, 2024	Silvan Tuerkcan	JMP Securities	$16.00	$10.86	47.33%	40.23%
Oct 14, 2024	Mani Foroohar	Leerink Partners	$13.00	$10.86	19.71%	13.94%
Sep 24, 2024	Yasmeen Rahimi	Piper Sandler	$30.00	$8.88	237.84%	162.93%

The latest Benitec Biopharma stock forecast, released on Oct 14, 2024 by Silvan Tuerkcan from JMP Securities, set a price target of $18.00, which represents a 65.75% increase from the stock price at the time of the forecast ($10.86), and a 57.76% increase from BNTC last price ($11.41).

Benitec Biopharma Price Target by Period

	1M	3M	12M
# Anlaysts	-	4	4
Avg Price Target	-	$19.25	$19.25
Last Closing Price	$11.41	$11.41	$11.41
Upside/Downside	-100.00%	68.71%	68.71%

In the current month, the average price target of Benitec Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Benitec Biopharma's last price of $11.41. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 15, 2024	Piper Sandler	Overweight	Overweight	Hold
Oct 18, 2024	Piper Sandler	Overweight	Overweight	Hold
Oct 15, 2024	Oppenheimer		Outperform	Initialise
Oct 14, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Oct 14, 2024	JMP Securities	Outperform	Outperform	Hold
Oct 14, 2024	Leerink Partners	Outperform	Outperform	Hold
Sep 24, 2024	Piper Sandler	Overweight	Overweight	Hold
Sep 12, 2024	Guggenheim		Buy	Initialise
Jun 13, 2024	Piper Sandler		Overweight	Initialise

Benitec Biopharma's last stock rating was published by Piper Sandler on Nov 15, 2024. The company gave BNTC a "Overweight" rating, the same as its previous rate.

Benitec Biopharma Financial Forecast

Benitec Biopharma Revenue Forecast

	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 22	Mar 22	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$472.00K	$48.00K	$2.00K	$1.00K	$1.00K	$55.00K	$459.00K
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.68K	$52.36K	$6.66K	$6.56K	$45.61K	$90.67K	$183.58K
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.68K	$62.83K	$6.66K	$6.56K	$45.61K	$90.67K	$183.58K
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.68K	$41.89K	$6.66K	$6.56K	$45.61K	$90.67K	$183.58K
# Analysts	-	-	-	-	-	-	-	-	-	-	-	-	-	7	16	8	9	13	8	8
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	32.15%	0.92%	0.30%	0.15%	0.02%	0.61%	2.50%

Benitec Biopharma's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. BNTC's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $472.00K (Sep 22).

Benitec Biopharma EBITDA Forecast

	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 22	Mar 22	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	-	-	-	-	-	-	-	-	-	-	-	-	-	7	16	8	9	13	8	8
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-4.48M	$-3.38M	$-3.90M	$-3.80M	$-3.14M	$-2.63M	$-2.84M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	$-14.68K	$-3.44M	$-6.66K	$-6.56K	$-45.61K	$-90.67K	$-183.58K
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	$-14.68K	$-2.75M	$-6.66K	$-6.56K	$-45.61K	$-90.67K	$-183.58K
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	$-14.68K	$-4.12M	$-6.66K	$-6.56K	$-45.61K	$-90.67K	$-183.58K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	305.02%	0.98%	585.53%	578.31%	68.82%	28.97%	15.46%

undefined analysts predict BNTC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Benitec Biopharma's previous annual EBITDA (undefined) of $NaN.

Benitec Biopharma Net Income Forecast

	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 22	Mar 22	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	-	-	-	-	-	-	-	-	-	-	-	-	-	7	16	8	9	13	8	8
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-5.61M	$-3.09M	$-4.00M	$-3.91M	$-3.25M	$-2.72M	$-2.94M
Avg Forecast	$-7.31M	$-7.38M	$-7.62M	$-7.77M	$-8.23M	$-9.00M	$-8.85M	$-8.69M	$-14.10M	$-13.54M	$-13.23M	$-8.46M	$-6.49M	$-19.73M	$-3.57M	$-85.56M	$-77.03M	$-67.47M	$-88.58M	$-2.17M
High Forecast	$-7.31M	$-7.38M	$-7.62M	$-7.77M	$-8.23M	$-9.00M	$-8.85M	$-8.69M	$-14.10M	$-3.57M	$-3.49M	$-8.46M	$-6.49M	$-19.73M	$-2.86M	$-85.56M	$-77.03M	$-67.47M	$-88.58M	$-1.74M
Low Forecast	$-7.31M	$-7.38M	$-7.62M	$-7.77M	$-8.23M	$-9.00M	$-8.85M	$-8.69M	$-14.10M	$-30.54M	$-30.06M	$-8.46M	$-6.49M	$-19.73M	$-4.29M	$-85.56M	$-77.03M	$-67.47M	$-88.58M	$-2.61M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.28%	0.86%	0.05%	0.05%	0.05%	0.03%	1.35%

Benitec Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BNTC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Benitec Biopharma SG&A Forecast

	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 22	Mar 22	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	-	-	-	-	-	-	-	-	-	-	-	-	-	7	16	8	9	13	8	8
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.92M	$1.34M	$1.54M	$1.03M	$2.11M	$1.84M	$1.90M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.10M	$3.94M	$501.47K	$493.95K	$3.43M	$6.82M	$13.81M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.10M	$4.73M	$501.47K	$493.95K	$3.43M	$6.82M	$13.81M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.10M	$3.15M	$501.47K	$493.95K	$3.43M	$6.82M	$13.81M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.74%	0.34%	3.06%	2.08%	0.62%	0.27%	0.14%

Benitec Biopharma's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to BNTC last annual SG&A of $1.92M (Sep 22).

Benitec Biopharma EPS Forecast

	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 22	Mar 22	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	-	-	-	-	-	-	-	-	-	-	-	-	-	7	16	8	9	13	8	8
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.52	$-0.38	$-0.49	$-0.82	$-0.76	$-2.45	$-0.01
Avg Forecast	$-0.69	$-0.69	$-0.72	$-0.73	$-0.77	$-0.85	$-0.83	$-0.82	$-1.32	$-1.27	$-1.24	$-0.79	$-0.73	$-4.86	$-9.96	$-21.07	$-18.97	$-16.62	$-21.82	$-0.16
High Forecast	$-0.69	$-0.69	$-0.72	$-0.73	$-0.77	$-0.85	$-0.83	$-0.82	$-1.32	$-0.34	$-0.33	$-0.79	$-0.73	$-4.86	$-9.96	$-21.07	$-18.97	$-16.62	$-21.82	$-0.16
Low Forecast	$-0.69	$-0.69	$-0.72	$-0.73	$-0.77	$-0.85	$-0.83	$-0.82	$-1.32	$-2.87	$-2.82	$-0.79	$-0.73	$-4.86	$-9.96	$-21.07	$-18.97	$-16.62	$-21.82	$-0.16
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.11%	0.04%	0.02%	0.04%	0.05%	0.11%	0.05%

According to undefined Wall Street analysts, Benitec Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BNTC previous annual EPS of $NaN (undefined).

Benitec Biopharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ZURA	Zura Bio	$2.51	$10.00	298.41%	Buy
NXTC	NextCure	$0.90	$3.00	233.33%	Buy
BNTC	Benitec Biopharma	$12.77	$20.33	59.20%	Buy
CAPR	Capricor Therapeutics	$13.20	$15.38	16.52%	Buy

BNTC Forecast FAQ

Is Benitec Biopharma a good buy?

Yes, according to 5 Wall Street analysts, Benitec Biopharma (BNTC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of BNTC's total ratings.

What is BNTC's price target?

Benitec Biopharma (BNTC) average price target is $20.33 with a range of $13 to $30, implying a 78.18% from its last price of $11.41. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Benitec Biopharma stock go up soon?

According to Wall Street analysts' prediction for BNTC stock, the company can go up by 78.18% (from the last price of $11.41 to the average price target of $20.33), up by 162.93% based on the highest stock price target, and up by 13.94% based on the lowest stock price target.

Can Benitec Biopharma stock reach $20?

BNTC's average twelve months analyst stock price target of $20.33 supports the claim that Benitec Biopharma can reach $20 in the near future.

What are Benitec Biopharma's analysts' financial forecasts?

Benitec Biopharma's analysts financial forecasts for the fiscal year (Jun 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-34.77M (high $-34.77M, low $-34.77M), average SG&A $0 (high $0, low $0), and average EPS is $-3.266 (high $-3.266, low $-3.266). BNTC's analysts financial forecasts for the fiscal year (Jun 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.078M (high $-30.078M, low $-30.078M), average SG&A $0 (high $0, low $0), and average EPS is $-2.826 (high $-2.826, low $-2.826).

Did the BNTC's actual financial results beat the analysts' financial forecasts?

Based on Benitec Biopharma's last annual report (Jun 2021), the company's revenue was $59K, which missed the average analysts forecast of $149.51K by -60.54%. Apple's EBITDA was $-13.279M, beating the average prediction of $-150K by 8781.62%. The company's net income was $-14.061M, missing the average estimation of $-319M by -95.59%. Apple's SG&A was $6.51M, missing the average forecast of $11.25M by -42.12%. Lastly, the company's EPS was $-3.27, missing the average prediction of $-78.478 by -95.83%. In terms of the last quarterly report (Sep 2022), Benitec Biopharma's revenue was $472K, beating the average analysts' forecast of $14.68K by 3115.04%. The company's EBITDA was $-4.478M, beating the average prediction of $-14.681K by 30402.01%. Benitec Biopharma's net income was $-5.606M, missing the average estimation of $-19.734M by -71.59%. The company's SG&A was $1.92M, beating the average forecast of $1.1M by 73.79%. Lastly, the company's EPS was $-0.52, missing the average prediction of $-4.86 by -89.30%